Drug-polymer conjugates coupled to a peptidic carrier
First Claim
Patent Images
1. A monodisperse macromolecular conjugate composition for in-vivo delivery of a therapeutic agent comprising a peptidic carrier reversibly or irreversibly conjugated with:
- (a) one or more effectors and (b) one or more therapeutic agents, wherein said peptidic carrier comprises at least two different orthogonal pendant reactive groups each for specific attachment of a predetermined effector or therapeutic agent and at least one effector or therapeutic agent is attached to at least one of said pendant reactive groups on said peptidic carrier via a water-soluble polymer, and wherein said peptidic carrier comprises an amino acid sequence selected from the group consisting of;
Cys-beta Ala-Lys (SEQ ID NO;
1);
Cys-(beta Ala-Lys)6 (SEQ ID NO;
2);
Acetyl-Cys-(beta Ala-beta Ala-Lys)2-Amide (SEQ ID NO;
3);
Acetyl-Cys-(beta Ala-(beta Ala-Lys)4-Amide (SEQ ID NO;
4); and
Cys-(beta Ala-beta Ala-Lys)2 (SEQ ID NO;
5).
1 Assignment
0 Petitions
Accused Products
Abstract
Monodisperse macromolecular conjugate compositions of a peptidic carrier irreversibly or reversibly conjugated with one or more effectors and one or more therapeutic agents, wherein at least one effector or therapeutic agent is attached to a pendant reactive group on said peptidic carrier via a water-soluble polymer. Monodispersity is obtained through the use of orthogonal and separate conjugation reactions.
6 Citations
42 Claims
-
1. A monodisperse macromolecular conjugate composition for in-vivo delivery of a therapeutic agent comprising a peptidic carrier reversibly or irreversibly conjugated with:
- (a) one or more effectors and (b) one or more therapeutic agents, wherein said peptidic carrier comprises at least two different orthogonal pendant reactive groups each for specific attachment of a predetermined effector or therapeutic agent and at least one effector or therapeutic agent is attached to at least one of said pendant reactive groups on said peptidic carrier via a water-soluble polymer, and wherein said peptidic carrier comprises an amino acid sequence selected from the group consisting of;
Cys-beta Ala-Lys (SEQ ID NO;
1);
Cys-(beta Ala-Lys)6 (SEQ ID NO;
2);
Acetyl-Cys-(beta Ala-beta Ala-Lys)2-Amide (SEQ ID NO;
3);Acetyl-Cys-(beta Ala-(beta Ala-Lys)4-Amide (SEQ ID NO;
4); and
Cys-(beta Ala-beta Ala-Lys)2 (SEQ ID NO;
5). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42)
- (a) one or more effectors and (b) one or more therapeutic agents, wherein said peptidic carrier comprises at least two different orthogonal pendant reactive groups each for specific attachment of a predetermined effector or therapeutic agent and at least one effector or therapeutic agent is attached to at least one of said pendant reactive groups on said peptidic carrier via a water-soluble polymer, and wherein said peptidic carrier comprises an amino acid sequence selected from the group consisting of;
-
39. A monodisperse macromolecular conjugate composition comprising a peptidic carrier, wherein said peptidic carrier comprises at least two different orthogonal pendant reactive groups, wherein at least one of said pendant reactive groups on said peptidic carrier is attached to a water-soluble polymer, and wherein said peptidic carrier comprises an amino acid sequence selected from the group consisting of:
- Cys-beta Ala-Lys (SEQ ID NO;
1);
Cys-(beta Ala-Lys)6(SEQ ID NO;
2);
Acetyl-Cys-(beta Ala-beta Ala-Lys)2-Amide (SEQ ID NO;
3);
Acetyl-Cys-(beta Ala-(beta Ala-Lys)4-Amide (SEQ ID NO;
4); and
Cys-(beta Ala-beta Ala-Lys)2 (SEQ ID NO;
5).
- Cys-beta Ala-Lys (SEQ ID NO;
Specification